Abbisko Therapeutics Announces Positive Preliminary Phase 2 Results with Lavengratinib (ABSK061) for the Treatment of Achondroplasia

Phase 2positiveLavengratinibPositive

AI Analysis

Summary

Abbisko Therapeutics announced positive preliminary Phase 2 efficacy results for lavengratinib (ABSK061) in the treatment of achondroplasia. The data represents a meaningful advancement in the clinical development of the selective candidate.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Positive preliminary efficacy results from Phase II clinical study

Importance:7/10

Sentiment:

0.75

Phase 2 dataAchondroplasiaClinical trialLavengratinibHong Kong listed

Related Companies

$2256.HK

Read the original article

Published by PR Newswire Biotech on September 21, 2026 1:00 AM

Read Original